Title: MS275 as Class I HDAC inhibitor displayed therapeutic potential on malignant ascites
by iTRAQ-based quantitative proteomic analysis
Version: 4 Date: 06 Jan 2022
Reviewer's report:
The authors have made all the changes and I suggest acceptance in current form
Title: MS275 as Class I HDAC inhibitor displayed therapeutic potential on malignant ascites
by iTRAQ-based quantitative proteomic analysis
Version: 4 Date: 06 Jan 2022
Reviewer's report:
The authors have made all the changes and I suggest acceptance in current form
Please review this paper.
user
Title: MS275 as Class I HDAC inhibitor displayed therapeutic potential on malignant ascites
by iTRAQ-based quantitative proteomic analysis
Version: 4 Date: 06 Jan 2022
Reviewer's report:
The authors have made all the changes and I suggest acceptance in current form
assistant